<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40328">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581384</url>
  </required_header>
  <id_info>
    <org_study_id>15-278</org_study_id>
    <nct_id>NCT02581384</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors</brief_title>
  <official_title>Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is studying stereotactic body radiotherapy (SBRT) as a possible
      treatment for lung relapse of Ewing Sarcoma, Rhabdomyosarcoma, or Wilms Tumor. SBRT is a
      form of targeted radiotherapy that can treat very small tumors using a few large doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Pilot Study, also known as a Phase I-II study, which means it is
      the first time investigators are examining this study intervention for patients with lung
      recurrence of Ewing Sarcoma, Rhabdomyosarcoma, or Wilms Tumor. This study tests the most
      appropriate dose, safety and efficacy of SBRT for the treatment of lung recurrence of Wilms
      tumor, rhabdomyosarcoma, or Ewing sarcoma in children. Standard radiotherapy is typically
      used to treat Ewing sarcoma and is used to treat lung recurrence. SBRT is being used to
      treat adults with small inoperable lung cancers; in such cases, SBRT has been shown to be
      effective and well-tolerated. SBRT is also used to treat bone metastases in adults and
      children.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>6 Months</time_frame>
    <description>The Phase I portion will evaluate the toxicity profile of each dose level and determine whether a given dose level could move forward to the Phase II portion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response</measure>
    <time_frame>6 weeks</time_frame>
    <description>Response after 6 weeks will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response</measure>
    <time_frame>2 years</time_frame>
    <description>The Kaplan and Meier method will be used to measure relapse time elsewhere in the lung. All patients who takes part in the treatment will be monitored for toxicity, and the percent of patients with various toxicities will be calculated for each dose level.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Ewing Sarcoma</condition>
  <condition>Rhabdomyosarcoma</condition>
  <condition>Wilms Tumor</condition>
  <arm_group>
    <arm_group_label>Stereotactic Body Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic Body Radiotherapy (SBRT)
Different dose levels will be used in the two cohorts.
Ewing sarcoma or rhabdomyosarcoma with non-renal tumor patients beginning at pre determine dose per protocol.
Wilms tumors or other primary renal tumors renal tumor patients beginning at pre determine dose per protocol.
The two cohorts will be enrolling patients independently and simultaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy (SBRT)</intervention_name>
    <arm_group_label>Stereotactic Body Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Ewing sarcoma, rhabdomyosarcoma or Wilms tumor or other primary renal
             tumor

          -  Age 8.0 to age 18.99 years

          -  Must be capable of treatment without general anesthesia

          -  Lesion size 8 mm - 3 cm

          -  Pulmonary metastases found at relapse (does not have to be first relapse); no more
             than 3 lesions per hemi-thorax

          -  Greater than 5 weeks from doxorubicin at the time of consent, with radiation to be
             initiated no less than 6 weeks from doxorubicin

          -  Greater than 3 weeks from intravenous chemotherapy except doxorubicin

          -  Informed consent/assent

          -  Life expectancy &gt; 3 months

          -  Pulmonary function FEV1 â‰¥ 50% of predicted

          -  Females, minorities and other underrepresented populations that are at risk to
             develop Ewing sarcoma and the other included malignancies

        Exclusion Criteria:

          -  Prior whole-lung or hemi-thorax irradiation of greater than or equal to 12 Gy (focal
             radiotherapy to the thorax is not an exclusion)

          -  Lesion larger than 3 cm in diameter

          -  Diffuse multiple (&gt; 3 per lung) metastases

          -  Active or new metastatic disease outside of the lung

          -  Lesions within 2 cm of central structures defined as:

        Tumor within or touching the zone of the proximal bronchial tree, defined as a volume 2 cm
        in all directions around the proximal bronchial tree (carina, right and left main bronchi,
        right and left upper lobe bronchi, intermedius bronchus, right middle lobe bronchus,
        lingular bronchus, right and left lower lobe bronchi).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Marcus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen J Marcus, MD</last_name>
    <phone>617-355-8399</phone>
    <email>kmarcus@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Marcus, MD</last_name>
      <phone>617-355-8399</phone>
    </contact>
    <investigator>
      <last_name>Karen J Marcus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Janeway, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Mullen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Marcus, MD</last_name>
      <phone>617-355-8399</phone>
    </contact>
    <investigator>
      <last_name>Karen Marcus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen J Marcus, MD</last_name>
      <phone>617-355-8399</phone>
    </contact>
    <investigator>
      <last_name>Karen J Marcus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Janeway, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Mullen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 3, 2016</lastchanged_date>
  <firstreceived_date>October 19, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Boston</investigator_affiliation>
    <investigator_full_name>Karen J Marcus, MD</investigator_full_name>
    <investigator_title>Karen J Marcus, M.D.</investigator_title>
  </responsible_party>
  <keyword>Ewing Sarcoma</keyword>
  <keyword>Rhabdomyosarcoma</keyword>
  <keyword>Wilms Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
